Cargando…

Results of sustained long-term use of interferon beta-1a in a community-based cohort of patients with relapsing multiple sclerosis

BACKGROUND: Few studies have evaluated long-term efficacy of interferon beta-1a in large community-based cohorts. OBJECTIVE: Evaluate time to relapse, relapse rate, and disability progression in patients treated with intramuscular interferon beta-1a. METHODS: A retrospective review of medical record...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cohan, Stanley, Chen, Chiayi, Baraban, Elizabeth, Stuchiner, Tamela, Grote, Lois, Rodriguez, Monica
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2015
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4937628/ https://www.ncbi.nlm.nih.gov/pubmed/27536455 http://dx.doi.org/10.3109/21556660.2015.1010650

Ejemplares similares

MRI utility in the detection of disease activity in clinically stable patients with multiple sclerosis: a retrospective analysis of a community based cohort
por: Cohan, Stanley, et al.
Publicado: (2016)

Clinical outcomes of patients with multiple sclerosis treated with ocrelizumab in a US community MS center: an observational study
por: Smoot, Kyle, et al.
Publicado: (2021)

Quality of life among injectable and oral disease-modifying therapy users in the Pacific Northwest Multiple Sclerosis Registry
por: Stuchiner, Tamela, et al.
Publicado: (2020)

Advancing Care and Outcomes for African American Patients With Multiple Sclerosis
por: Okai, Annette F., et al.
Publicado: (2022)

The results of a 24-month controlled, prospective study of relapsing multiple sclerosis patients at risk for progressive multifocal encephalopathy, who switched from prolonged use of natalizumab to teriflunomide
por: Cohan, Stanley, et al.
Publicado: (2021)

Sphingosine-1-Phosphate: Its Pharmacological Regulation and the Treatment of Multiple Sclerosis: A Review Article
por: Cohan, Stanley, et al.
Publicado: (2020)

Therapeutic efficacy of monthly subcutaneous injection of daclizumab in relapsing multiple sclerosis
por: Cohan, Stanley
Publicado: (2016)

Profile of PEGylated interferon beta in the treatment of relapsing-remitting multiple sclerosis
por: Cocco, Eleonora, et al.
Publicado: (2015)

The innovative development in interferon beta treatments of relapsing‐remitting multiple sclerosis
por: Madsen, Claus
Publicado: (2017)

Outcomes of Stable Multiple Sclerosis Patients Staying on Initial Interferon Beta Therapy Versus Switching to Another Interferon Beta Therapy: A US Claims Database Study
por: Cohan, Stanley, et al.
Publicado: (2018)

Interferons and Multiple Sclerosis: Lessons from 25 Years of Clinical and Real-World Experience with Intramuscular Interferon Beta-1a (Avonex)
por: Cohan, Stanley L., et al.
Publicado: (2021)

Review of interferon beta-1b in the treatment of early and relapsing multiple sclerosis
por: Paolicelli, Damiano, et al.
Publicado: (2009)

Injectable interferon beta-1b for the treatment of relapsing forms of multiple sclerosis
por: Jankovic, Slobodan M
Publicado: (2010)

Approved Beta Interferons in Relapsing-Remitting Multiple Sclerosis: Is There an Odd One Out?
por: Clapin, Alexis
Publicado: (2012)

The Assessment for Disinvestment of Intramuscular Interferon Beta for Relapsing-Remitting Multiple Sclerosis in Brazil
por: Lemos, Livia Lovato Pires de, et al.
Publicado: (2017)

Beta-interferons in multiple sclerosis
por: Aggarwal, Sourabh, et al.
Publicado: (2010)

Acute Lymphoblastic Leukemia in a Man Treated With Fingolimod for Relapsing Multiple Sclerosis
por: Cohan, Stanley, et al.
Publicado: (2015)

Atorvastatin added to interferon beta for relapsing multiple sclerosis: a randomized controlled trial
por: Kamm, Christian Philipp, et al.
Publicado: (2012)

Reducing return of disease activity in patients with relapsing multiple sclerosis transitioned from natalizumab to teriflunomide: 12-month interim results of teriflunomide therapy
por: Cohan, Stanley L, et al.
Publicado: (2019)

Improved cognitive outcomes in patients with relapsing–remitting multiple sclerosis treated with daclizumab beta: Results from the DECIDE study
por: Benedict, Ralph HB, et al.
Publicado: (2017)

IN VITRO ASSESSMENT OF THE BIOLOGIC ACTIVITY OF INTERFERON BETA FORMULATIONS USED FOR THE TREATMENT OF RELAPSING MULTIPLE SCLEROSIS
por: Scagnolari, Carolina, et al.
Publicado: (2014)

Prevalence of neutralising antibodies to interferon-beta and clinical response in Chinese patients with relapsing multiple sclerosis
por: Lau, Alexander Y, et al.
Publicado: (2017)

Myelin water imaging in relapsing multiple sclerosis treated with ocrelizumab and interferon beta-1a
por: Kolind, Shannon, et al.
Publicado: (2022)

The effect of intramuscular interferon beta-1a on spinal cord volume in relapsing-remitting multiple sclerosis
por: Dupuy, Sheena L., et al.
Publicado: (2016)

Cost-effectiveness of Teriflunomide Compared to Interferon Beta-1b for Relapsing Multiple Sclerosis Patients in China
por: Xu, Yan, et al.
Publicado: (2019)

Emerging Methods for Evaluating the Effectiveness of Intramuscular Interferon Beta-1a for Relapsing-Remitting Multiple Sclerosis
por: Foley, John F., et al.
Publicado: (2013)

Azathioprine versus Beta Interferons for Relapsing-Remitting Multiple Sclerosis: A Multicentre Randomized Non-Inferiority Trial
por: Massacesi, Luca, et al.
Publicado: (2014)

The Cost of Relapsing-Remitting Multiple Sclerosis Patients Who Develop Neutralizing Antibodies during Interferon Beta Therapy
por: Paolicelli, Damiano, et al.
Publicado: (2016)

‘Beta-interferons’ and ‘oligoclonal bands’ in multiple sclerosis in India
por: Hassan, K. M.
Publicado: (2011)

Thrombotic Thrombocytopenic Purpura in Interferon Beta-1a-Treated Patient Diagnosed with Relapsing-Remitting Multiple Sclerosis: A Case Report
por: Plesa, Cristina-Florentina, et al.
Publicado: (2022)

Safety and efficacy of daclizumab beta in patients with relapsing multiple sclerosis in a 5-year open-label study (EXTEND): final results following early termination
por: Kappos, Ludwig, et al.
Publicado: (2021)

Mycophenolate mofetil in combination with interferon beta-1a in the treatment of relapsing-remitting multiple sclerosis: A preliminary study
por: Etemadifar, Masoud, et al.
Publicado: (2011)

Atorvastatin Added to Interferon Beta for Relapsing Multiple Sclerosis: 12-Month Treatment Extension of the Randomized Multicenter SWABIMS Trial
por: Kamm, Christian P., et al.
Publicado: (2014)

Comparison of The Expression of miR-326 between Interferon beta Responders and Non-Responders in Relapsing-Remitting Multiple Sclerosis
por: Fattahi, Mahtab, et al.
Publicado: (2020)

Comparative Efficacy and Safety of Ozanimod and Dimethyl Fumarate for Relapsing-Remitting Multiple Sclerosis Using Matching-Adjusted Indirect Comparison
por: Cohan, Stanley, et al.
Publicado: (2021)

Response to Interferon-Beta Treatment in Afro-Caribbeans with Multiple Sclerosis
por: Jeannin, S., et al.
Publicado: (2011)

Beta‐interferon exposure and onset of secondary progressive multiple sclerosis
por: Zhang, T., et al.
Publicado: (2015)

Thrombotic Microangiopathy in Interferon‐beta‐Treated Multiple Sclerosis Patient
por: Malekzadeh, Masoud Mohammad, et al.
Publicado: (2020)

Effectiveness of Dimethyl Fumarate in Patients With Relapsing Multiple Sclerosis Switching After Suboptimal Response to Glatiramer Acetate, Including Patients With Early Multiple Sclerosis: Subgroup Analysis of RESPOND
por: Repovic, Pavle, et al.
Publicado: (2020)

Pregnancy outcomes in interferon-beta-exposed patients with multiple sclerosis: results from the European Interferon-beta Pregnancy Registry
por: Hellwig, Kerstin, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_j84c88bd3jjsedu50mruknqf15